By identifying patients at the time of diagnosis, our advanced AI-enabled patient recruitment platform compresses study timelines by finding the best-suited patients for clinical trials.
Find the right patients for the right trials, faster.
The challenge facing BioPharma and CROs is finding patients to fill trials. The complexity and siloing of patient data means eligible patients are slow to be identified, or worse, missed.
In addition, the vast majority of patients are seen in community settings and their care teams are left out of the clinical research loop altogether.
What if you could increase your visibility with healthcare providers and sponsored sites to accelerate trials to completion?
Our AI-driven cloud platform, VIPER, identifies and recruits patients at the time of diagnosis, accelerating trial recruitment to bring game-changing therapies to market sooner.
Embedded at institutions around the globe, VIPER integrates and filters patient data to match cases against inclusion and exclusion criteria and flags potential molecular testing to be completed.
In addition, VIPER pulls in patients from community settings to nearby trial sites. VIPER provides real-time dashboard and alerting capabilities to proactively track trial performance and new case activity at the study and site levels to compress study timelines.
VIPER is a unique patient recruitment tool specifically designed to inform and educate care teams of potential trial participants earlier than alternative methods through optimizing their enrollment process and not allowing patients to slip through the cracks with molecular testing notifications and community oncologist engagement.
AIVITA Biomedical is at the forefront of developing clinical-stage cell-based treatments in oncology. We know that there are patients that would qualify to participate in our studies but never get the opportunity to consider the studies as a care option. I am encouraged that Deep Lens has developed a promising solution to tackle some of the underlying obstacles that are challenging to our sites, that will help AIVITA Biomedical speed bring our therapies to market faster.